The Cigna Group
Loading chart...
Item 1. BUSINESS
OVERVIEW
The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company.
| Our Focused Mission | ||||||
The Cigna Group is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve by staying grounded in the needs of our customers and patients - delivering a personalized, transparent and affordable health care experience. We focus on leading the way to partner and innovate solutions for better health. | ||||||
At The Cigna Group our global workforce of approximately 67,700 colleagues strives to fulfill our mission to improve the health and vitality of more than 185 million customer relationships in more than 30 markets and jurisdictions (as of December 31, 2025). We play an important role in the health care system, and the breadth and depth of our customer relationships - as well as our approximately 1.7 million relationships with health care providers, clinics and facilities - give us opportunities to drive positive change.
We have two segments: Evernorth Health Services® and Cigna Healthcare®. The Evernorth Health Services segment, through our Pharmacy Benefit Services and Specialty and Care Services operating segments, provides independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. Cigna Healthcare, the health benefits segment of The Cigna Group, provides comprehensive medical and coordinated solutions to customers and clients served by our U.S. Healthcare and International Health operating segments.
Together, Evernorth Health Services and Cigna Healthcare combine pharmacy and medical capabilities to create solutions that improve affordability, transparency and health outcomes. This combination helps us anticipate needs, accelerate innovation and deliver personalized experiences for customers and patients at scale.
Information about Segments
We present the financial results of our businesses in the following segments (see the "Executive Overview" section of Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") located in Part II, Item 7 of this Form 10-K for a financial summary):
Evernorth Health Services includes our Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.
Cigna Healthcare includes our U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers.
Other Operations comprises the remainder of our business operations, which includes certain continuing, run-off and other non-strategic businesses.
Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.
See the "Executive Overview - Key Transactions and Business Developments" section of our Management's Discussion and Analysis of Financial Condition and Results of Operations located in Part II, Item 7 of this Form 10-K for discussion of key developments impacting the segments.
1
Commitments to Better
Through our Commitments to Better, we embarked on a new, multiyear chapter to accelerate our ongoing evolution and industry leadership. We know we play an important role in a health care system that needs changing for the better, and we are determined to lead that change for the health and vitality of those we serve. We have many roles in the health care system to deliver better outcomes to our customers, including helping to make healthcare more affordable, administering health care claims and working to reduce health care waste. The Cigna Group has established five key areas of focus, and several initial specific actions, to improve the health of its customers and increase the value it provides:
•Easier access to care: address challenges customers face by making processes simpler, easier and faster.
•Better support: provide customers with more support and resources to navigate the health care system.
•Better value: drive better value for customers and patients.
•Accountability: stand behind our commitments to our customers and patients.
•Transparency: provide information on how we are continuously improving to serve our customers better.
Other Information
The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981.
The financial information included in this Form 10-K for the fiscal year ended December 31, 2025 is presented in conformity with accounting principles generally accepted in the United States of America ("GAAP") unless otherwise indicated. Industry rankings and percentages set forth herein are for the year ended December 31, 2025, unless otherwise indicated. In addition, statements set forth in this document concerning our rank or position in an industry or particular line of business have been developed internally based on publicly available information unless otherwise noted.
You can access our website at http://www.thecignagroup.com to learn more about our company. We make annual, quarterly and current reports and proxy statements and amendments to those reports available, free of charge, through our website as soon as reasonably practicable after we electronically file these materials with, or furnish them to, the Securities and Exchange Commission ("SEC"). We also use our website as a means of disclosing material information and for complying with our disclosure obligations under the SEC's Regulation FD (Fair Disclosure). Important information, including news releases, analyst presentations and financial information regarding The Cigna Group is routinely posted on our website. Accordingly, investors should monitor the Investor Relations portion of our website, in addition to following our press releases, SEC filings, and public conference calls and webcasts. The information contained on, or that may be accessed through, our website is neither incorporated by reference into nor a part of this report. See also "Code of Ethics and Other Corporate Governance Disclosures" in Part III, Item 10 of this Form 10-K for additional information regarding the availability of our Codes of Ethics on our website.
EVERNORTH HEALTH SERVICES
Evernorth Health Services includes our Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.
Evernorth Health Services offers a full suite of products and services that both (a) enables our clients to combine our products and services to create a comprehensive benefit offering designed to manage prescription drugs and provide independent and coordinated health solutions and capabilities and (b) addresses the needs of a shared customer base across both operating segments of Evernorth Health Services. Our ability to deliver this broad array of health care services on either a standalone or combined basis between its two operating segments enables us to drive incremental growth. Additionally, many Evernorth Health Services offerings are available within Cigna Healthcare solutions.
2
| How We Deliver | ||||||
•Deep clinical expertise in evaluating medicines, digital therapeutics and other health solutions for efficacy and value to assist clients in selecting a cost-effective formulary as well as in leveraging evidence-based guidelines to ensure patients receive the most medically appropriate treatments. | ||||||
•Affordable solutions that provide more value and align incentives between the patient, health care professional and plan sponsor. | ||||||
•Modular portfolio tailored to client needs, using the combined strengths and capabilities of Evernorth Health Services, as well as strategic partnerships, to deliver better, more efficient care for patients; better experiences for clients, providers and customers; and enhanced choices for clients and customers through our open architecture model. | ||||||
•Talented, experienced and caring people who operate in a culture of innovation and partnership to solve complex problems across a fragmented health care ecosystem, fueled by data and expertise that drives purposeful innovation. | ||||||
•Commitment to improving the health care experience for patients and physicians through easier access to care, better support, better value, accountability and transparency. | ||||||
Principal Products and Services
Pharmacy Benefit Services
•Pharmacy Benefits. We drive high-quality, cost-effective pharmacy care through a range of services. We adjudicate drug claims from retail network participants and provide retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and other services.
◦Retail Pharmacy Network Administration. We contract with retail pharmacies to provide prescription drugs to customers of the pharmacy benefit plans our clients offer. We negotiate with pharmacies throughout the United States to discount drug prices and offer national and regional network options responsive to client preferences related to cost containment, convenience of access for customers and network performance.
◦Benefits Design Consultation. We consult with our clients on how best to structure and leverage the pharmacy benefit to meet plan objectives for affordable and sustainable access to the prescription medications customers need to stay healthy and to ensure the safe and effective use of those medications.
◦Drug Utilization Review. When pharmacies submit claims for prescription drugs to us, we review them in real time for health and safety. If issues are detected, we then alert the dispensing pharmacy. Clients may also choose to enroll in programs that result in communications about potential therapy concerns being sent to prescribers after the initial claim submission.
◦
Loading financial statements...
Financial statements
data from SEC XBRL filings. Values are as-reported; restatements supersede originals. Values reported in .
| Line item |
|---|
| Period ending |
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide information to assist you in better understanding and evaluating our financial condition as of March 31, 2026 compared with December 31, 2025 and our results of operations for the three months ended March 31, 2026 compared with the same period last year, and is intended to help you understand the ongoing trends in our business. We encourage you to read this MD&A in conjunction with our Consolidated Financial Statements included in Part I, Item 1 in this Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). In particular, we encourage you to refer to the "Risk Factors" contained in Part I, Item 1A in our 2025 Form 10-K.
Unless otherwise indicated, financial information in this MD&A is presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). See Note 2 to the Consolidated Financial Statements in our 2025 Form 10-K for additional information regarding the Company's significant accounting policies and see Note 2 to the Consolidated Financial
27
Statements in this Form 10-Q for updates to those policies resulting from adopting new accounting guidance, if any. The preparation of interim consolidated financial statements necessarily relies heavily on estimates. This and certain other factors call for caution in estimating full-year results based on interim results of operations. In some of our financial tables in this MD&A, we present either percentage changes or "N/M" when those changes are so large as to become not meaningful. Changes in percentages are expressed in basis points ("bps").
In this MD&A, our consolidated measures "adjusted income from operations," earnings per share on that same basis and "adjusted revenues" are not determined in accordance with GAAP and should not be viewed as substitutes for the most directly comparable GAAP measures of "shareholders' net income," "earnings per share" and "total revenues." We also use pre-tax adjusted income (loss) from operations and adjusted revenues to measure the results of our segments.
The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability. We define adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the below Financial Highlights section for a reconciliation of consolidated adjusted income from operations to shareholders' net income.
The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the below Financial Highlights section for a reconciliation of consolidated adjusted revenues to total revenues.
See Note 15 to the Consolidated Financial Statements for additional discussion of these metrics and a reconciliation of income (loss) before income taxes to pre-tax adjusted income (loss) from operations, as well as a reconciliation of Total revenues to adjusted revenues. Note 15 to the Consolidated Financial Statements also explains that segment revenues include both external revenues and sales between segments that are eliminated in Corporate. Ratios presented in the segment discussion exclude the same items as adjusted revenues and pre-tax adjusted income (loss) from operations.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy, and strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas and the impact of developing inflationary and interest rate pressures; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions and their expected benefits; and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider
28
marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in Part I, Item 1A - "Risk Factors" in our 2025 Form 10-K, discussed in Part II, Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2025 Form 10-K, and as described from time to time in our future reports filed with the Securities and Exchange Commission.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.
EXECUTIVE OVERVIEW
The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. For further information on our business and strategy, see Part I, Item 1 - "Business" in our 2025 Form 10-K.
29
Financial Highlights
Consolidated Results of Operations (GAAP basis) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (Dollars in millions) | 2026 | 2025 | Change | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacy revenues | $ | 54,037 | $ | 48,633 | 11 | % | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | 9,812 | 12,736 | (23) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fees and other revenues | 4,443 | 3,895 | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net investment income | 202 | 238 | (15) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | 68,494 | 65,502 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacy and other service costs | 54,100 | 48,398 | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical costs and other benefit expenses | 7,924 | 10,498 | (25) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | 3,722 | 4,213 | (12) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 390 | 422 | (8) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total benefits and expenses | 66,136 | 63,531 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Income from operations | 2,358 | 1,971 | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interest expense and other | (357) | (362) | (1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on sale of businesses | 11 | 41 | (73) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Net investment gains (losses) | 258 | (2) | N/M | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Income before income taxes | 2,270 | 1,648 | 38 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total income taxes | 409 | 239 | 71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income | 1,861 | 1,409 | 32 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Less: Net income attributable to noncontrolling interests | 207 | 86 | 141 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Shareholders' net income | $ | 1,654 | $ | 1,323 | 25 | % | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Consolidated effective tax rate | 18.0 | % | 14.5 | % | 350 | bps | ||||||||||||||||||||||||||||||||||||||||||||||||||
30
Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations | ||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| (In millions) | Pre-tax | After-tax | Pre-tax | After-tax | ||||||||||||||||||||||||||||||||||||||||||
Shareholders' net income | $ | 1,654 | $ | 1,323 | ||||||||||||||||||||||||||||||||||||||||||
| Adjustments to reconcile to adjusted income from operations | ||||||||||||||||||||||||||||||||||||||||||||||
Net investment (gains) (1) | $ | (235) | (233) | $ | (48) | (48) | ||||||||||||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 390 | 315 | 422 | 336 | ||||||||||||||||||||||||||||||||||||||||||
| Special items | ||||||||||||||||||||||||||||||||||||||||||||||
Strategic optimization program | 380 | 290 | 215 | 163 | ||||||||||||||||||||||||||||||||||||||||||
Integration and transaction-related costs | 35 | 27 | 216 | 164 | ||||||||||||||||||||||||||||||||||||||||||
Deferred tax expenses, net | — | 16 | — | 17 | ||||||||||||||||||||||||||||||||||||||||||
(Gain) on sale of businesses | — | (3) | (41) | (115) | ||||||||||||||||||||||||||||||||||||||||||
(Benefits) associated with litigation matters | (11) | (8) | — | — | ||||||||||||||||||||||||||||||||||||||||||
| Total special items | $ | 404 | 322 | $ | 390 | 229 | ||||||||||||||||||||||||||||||||||||||||
Adjusted income from operations | $ | 2,058 | $ | 1,840 | ||||||||||||||||||||||||||||||||||||||||||
(1)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
Reconciliation of Shareholders' Net Income (GAAP) to Adjusted Income from Operations | ||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended March 31, | ||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||||||||||||||||||||||||
| (Diluted earnings per share) | Pre-tax | After-tax | Pre-tax | After-tax | ||||||||||||||||||||||||||||||||||||||||||
Shareholders' net income | $ | 6.26 | $ | 4.85 | ||||||||||||||||||||||||||||||||||||||||||
| Adjustments to reconcile to adjusted income from operations | ||||||||||||||||||||||||||||||||||||||||||||||
Net investment (gains) (1) | $ | (0.89) | (0.88) | $ | (0.18) | (0.18) | ||||||||||||||||||||||||||||||||||||||||
| Amortization of acquired intangible assets | 1.48 | 1.19 | 1.54 | 1.23 | ||||||||||||||||||||||||||||||||||||||||||
| Special items | ||||||||||||||||||||||||||||||||||||||||||||||
Strategic optimization program | 1.44 | 1.10 | 0.79 | 0.60 | ||||||||||||||||||||||||||||||||||||||||||
Integration and transaction-related costs | 0.13 | 0.10 | 0.79 | 0.60 | ||||||||||||||||||||||||||||||||||||||||||
Deferred tax expenses, net | — | 0.06 | — | 0.06 | ||||||||||||||||||||||||||||||||||||||||||
(Gain) on sale of businesses | — | (0.01) | (0.15) | (0.42) | ||||||||||||||||||||||||||||||||||||||||||
(Benefits) associated with litigation matters | (0.04) | (0.03) | — | — | ||||||||||||||||||||||||||||||||||||||||||
| Total special items | $ | 1.53 | 1.22 | $ | 1.43 | 0.84 | ||||||||||||||||||||||||||||||||||||||||
Adjusted income from operations | $ | 7.79 | $ | 6.74 | ||||||||||||||||||||||||||||||||||||||||||
(1) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.
31
| Financial highlights by segment | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||
| (Dollars in millions, except per share amounts) | 2026 | 2025 | Change | ||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Adjusted revenues by segment | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Evernorth Health Services | $ | 58,442 | $ | 53,681 | 9 | % | |||||||||||||||||||||||||||||||||||||||||||||
| Cigna Healthcare | 11,477 | 14,482 | (21) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other Operations | 120 | 175 | (31) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate, net of eliminations | (1,522) | (2,886) | (47) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Adjusted revenues | 68,517 | 65,452 | 5 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net investment results from certain equity method investments | (23) | 50 | N/M | ||||||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | $ | 68,494 | $ | 65,502 | 5 | % | |||||||||||||||||||||||||||||||||||||||||||||
Shareholders' net income | $ | 1,654 | $ | 1,323 | 25 | % | |||||||||||||||||||||||||||||||||||||||||||||
Adjusted income from operations | $ | 2,058 | $ | 1,840 | 12 | % | |||||||||||||||||||||||||||||||||||||||||||||
| Earnings per share (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Shareholders' net income | $ | 6.26 | $ | 4.85 | 29 | % | |||||||||||||||||||||||||||||||||||||||||||||
Adjusted income from operations | $ | 7.79 | $ | 6.74 | 16 | % | |||||||||||||||||||||||||||||||||||||||||||||
| Pre-tax adjusted income (loss) from operations by segment | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Evernorth Health Services | $ | 1,466 | $ | 1,434 | 2 | % | |||||||||||||||||||||||||||||||||||||||||||||
| Cigna Healthcare | 1,514 | 1,287 | 18 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Other Operations | 27 | — | N/M | ||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate, net of eliminations | (404) | (411) | (2) | ||||||||||||||||||||||||||||||||||||||||||||||||
Consolidated pre-tax adjusted income from operations | 2,603 | 2,310 | 13 | ||||||||||||||||||||||||||||||||||||||||||||||||
Income attributable to noncontrolling interests | 226 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Recent insider activity
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | Kates Jamie G | Chief Accounting Officer | Sell | -899 | $298.61 | -$268,452 |
| 2026-05-12 | Cordani David | Chairman & CEO | Sell | -201,878 ×13 | $292.82 | -$59,114,186 |
Source: SEC Form 4 filings.
Next expected filings
- ~2026-07-30 10-Q expected by 2026-08-07 (in 1 day)
- ~2026-10-29 10-Q expected by 2026-11-06 (in 92 days)
- ~2027-02-25 10-K expected by 2027-02-28 (in 211 days)
- ~2027-04-29 10-Q expected by 2027-05-07 (in 274 days)
Predicted from historical filing cadence; not an SEC commitment.
Recent SEC filings
- 2026-04-30 8-K Earnings Release; Financial Statements and Exhibits
- 2026-04-30 10-Q Quarterly Report
- 2026-03-03 8-K Officer/Director Change; Regulation FD Disclosure; Financial Statements and Exhibits
- 2026-02-26 10-K Annual Report
- 2026-02-05 8-K Earnings Release; Financial Statements and Exhibits
- 2025-11-18 8-K Other Events
- 2025-10-30 10-Q Quarterly Report
- 2025-10-30 8-K Earnings Release; Financial Statements and Exhibits
- 2025-10-20 8-K Officer/Director Change
- 2025-09-04 8-K Material Agreement Entered; Material Financial Obligation; Other Events; Financial Statements and Exhibits
- 2025-07-31 10-Q Quarterly Report
- 2025-07-31 8-K Earnings Release; Financial Statements and Exhibits
- 2025-07-28 8-K/A Officer/Director Change
- 2025-06-02 8-K Officer/Director Change; Financial Statements and Exhibits
- 2025-05-02 10-Q Quarterly Report